IMMUNITYBIO, INC. Revenue from Contract with Customer, Excluding Assessed Tax
IMMUNITYBIO, INC. (IBRX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $51.24 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $51.24M, a 93.91% increase year-over-year.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $44.21M, a 167.64% increase year-over-year.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $38.28M, a 406.95% increase year-over-year.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $32.06M, a 425.07% increase year-over-year.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $113.29M, a 668.31% increase from fiscal 2024.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $14.74M, a 2270.58% increase from fiscal 2023.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $622.00K, a 159.17% increase from fiscal 2022.
- IMMUNITYBIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $240.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $51.24M 10-Q · filed 2026-08-04 | $95.45M 10-Q · filed 2026-08-04 | $133.73M derived: sum of 3 quarters · filed 2026-08-04 | $165.79M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $44.21M 10-Q · filed 2026-05-07 | $82.49M derived: sum of 2 quarters · filed 2026-05-07 | $114.55M derived: sum of 3 quarters · filed 2026-05-07 | $140.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $38.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $70.35M derived: sum of 2 quarters · filed 2026-02-23 | $96.77M derived: sum of 3 quarters · filed 2026-08-04 | $113.29M 10-K · filed 2026-02-23 |
| 2025-09-30 | $32.06M 10-Q · filed 2025-11-05 | $58.49M derived: sum of 2 quarters · filed 2026-08-04 | $75.00M 10-Q · filed 2025-11-05 | $82.56M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $26.43M 10-Q · filed 2026-08-04 | $42.94M 10-Q · filed 2026-08-04 | $50.49M derived: sum of 3 quarters · filed 2026-08-04 | $56.60M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $16.52M 10-Q · filed 2026-05-07 | $24.07M derived: sum of 2 quarters · filed 2026-05-07 | $30.18M derived: sum of 3 quarters · filed 2026-05-07 | $31.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $13.66M derived: sum of 2 quarters · filed 2026-02-23 | $14.71M derived: sum of 3 quarters · filed 2026-02-23 | $14.74M 10-K · filed 2026-02-23 |
| 2024-09-30 | $6.11M 10-Q · filed 2025-11-05 | $7.15M derived: sum of 2 quarters · filed 2025-11-05 | $7.19M 10-Q · filed 2025-11-05 | $7.33M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $1.05M 10-Q · filed 2025-08-05 | $1.09M 10-Q · filed 2025-08-05 | $1.23M derived: sum of 3 quarters · filed 2026-02-23 | $1.31M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $40.00K 10-Q · filed 2025-05-12 | $179.00K derived: sum of 2 quarters · filed 2026-02-23 | $261.00K derived: sum of 3 quarters · filed 2026-02-23 | $302.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $221.00K derived: sum of 2 quarters · filed 2026-02-23 | $262.00K derived: sum of 3 quarters · filed 2026-02-23 | $622.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | $82.00K 10-Q · filed 2024-11-12 | $123.00K derived: sum of 2 quarters · filed 2024-11-12 | $483.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $41.00K 10-Q · filed 2024-08-12 | $401.00K 10-Q · filed 2024-08-12 | ||
| 2022-12-31 | $240.00K 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |